Anti-CD64-anti-CD30 bispecific monoclonal antibody - Medarex

Drug Profile

Anti-CD64-anti-CD30 bispecific monoclonal antibody - Medarex

Alternative Names: H22xKi-4

Latest Information Update: 03 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors; IgG receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease

Most Recent Events

  • 03 May 2007 Discontinued - Phase-I for Hodgkin's disease in USA (unspecified route)
  • 03 Apr 2003 Phase-I clinical trials in Hodgkin's disease in USA (unspecified route)
  • 03 Apr 2003 A study has been added to the adverse events, pharmacokinetics, pharmacodynamic and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top